A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Financial Summary
| Share Statistics | ONCO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.0 | $252.6 | 2% |
|
| Shares Out (Mil) | 0.1 | 52.3 | 1% |
|
| Institutional Ownership | 100.0% | 92.1% | 99% |
|
| Float (Mil) | 3.7 | 40.2 | 9% |
|
| Beta | 2.72 | 0.95 | 97% |
|
| Avg Daily Volume (000s) | 410 | 455 | 56% |
|
| Price Change (52-week) |
(99.5%) | 52.9% | 1% |
|
| Growth | ONCO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (54.3%) | (9.9%) | 6% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ONCO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $38 | 1% |
|
| Net Income (TTM) (Mil) | ($10) | ($43) | 29% |
|
| EPS (TTM) | ($300.312) | ($1.600) | 0% |
|
| Operating Cash Flow (TTM) (Mil) | ($10) | ($31) | 19% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($2) | $180 | 3% |
|
| Valuation | ONCO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.02 | 2.56 | 0% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ONCO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 79.6% | 63.8% | 89% |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (57.7%) | (49.8%) | 10% |
|
| ROE | (123.3%) | (55.5%) | 8% |
|
| Liabilities to Assets | 20.8% | 30.3% | 13% |
|
| F-Score | 4 | 3 | na |
|
Onconetix, Inc. did not pass any screens on 7/31/2026.
